Neal Shore and Mark Tyson discuss advances in non-muscle invasive bladder cancer treatments, particularly for BCG unresponsive patients. They delve into the approval and data on nadofaragene firadenovec, a novel intravesical gene therapy, highlighting its efficacy and patient-friendly administration schedule. Dr. Tyson shares insights on the drug's mechanism, its clinical trial outcomes, and its operational aspects within clinical settings. Their conversation also touches on the challenges and strategies for integrating this therapy into practice, considering patient convenience and the logistical aspects of drug administration. Drs. Shore and Tyson discuss the broader implications for clinical trials and patient care in the bladder cancer treatment landscape, acknowledging the significance of this development in offering new hope to patients seeking alternatives to more invasive treatments.

Biographies:

Mark Tyson II, MD, MPH, Urologic Oncologist, Mayo Clinic, Scottsdale, AZ

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC